

October 10, 2022

The Manager, Listing Department  
The National Stock Exchange of India Ltd.  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
NSE Symbol : PANACEABIO

BSE Limited  
Corporate Relationship Department,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001  
BSE Scrip Code: 531349

**Re.: Press Release - Panacea Biotec receives awards worth US\$ 127.30 million for supply of Pentavalent Vaccine (DTwP-HepB-Hib) from UNICEF & PAHO**

Dear Sir/Madam,

Panacea Biotec Ltd. is delighted to inform that the Company has received long-term supply awards worth US\$ 127.30 million (around INR 1,040 Crore) from UNICEF and Pan American Health Organization (PAHO) for supply of its WHO pre-qualified fully liquid Pentavalent vaccine, Easyfive-TT® (DTwP-HepB-Hib).

UNICEF award is worth US\$ 98.755 million (~INR 813 Crore) for supply of ~99.70 million doses during calendar years 2023-2027 and PAHO award is worth US\$ 28.55 million (~INR 235 Crore) for supply ~24.83 million doses during calendar years 2023-2025.

A copy of the Press Release titled “**Panacea Biotec receives UNICEF & PAHO awards for supply of Pentavalent Vaccine (DTwP-HepB-Hib)**” being issued to the media, etc. in this regard is enclosed for your kind reference and record please.

Kindly acknowledge the receipt.

Thanking you,

Sincerely yours,

for **Panacea Biotec Ltd.**



**Vinod Goel**  
**Group CFO and Head Legal**  
**& Company Secretary**



Encl. As Above

B1 Extn. /G3, Mohan Co-op Indl. Estate,  
Mathura Road, New Delhi -110044  
Email: vinodgoel@panaceabiotec.com  
Phone: D.I.D. +91-11-4167 9015  
Fax: +91-11-4167 9070

**Panacea Biotec Ltd.**

CIN: L33117PB1984PLC022350

Registered Office: Ambala-Chandigarh Highway, Lalru - 140 501, Punjab, India. Ph.: +91-1762-505900, Fax: +91-1762-505906.  
e-mail: corporate@panaceabiotec.com website: www.panaceabiotec.com

Press Release

**Panacea Biotec receives UNICEF & PAHO awards for supply of Pentavalent Vaccine (DTwP-HepB-Hib)**

**New Delhi, India, October 10, 2022:** Panacea Biotec, one of India's leading biotechnology companies, has received long-term supply awards worth US\$ 127.30 million (around INR 1,040 Crore) from UNICEF and Pan American Health Organization (PAHO) for supply of its WHO pre-qualified fully liquid Pentavalent vaccine, Easyfive-TT® (DTwP-HepB-Hib).

UNICEF award is worth US\$ 98.755 million (~INR 813 Crore) for supply of ~99.70 million doses during calendar years 2023-2027 and PAHO award is worth US\$ 28.55 million (~INR 235 Crore) for supply ~24.83 million doses during calendar years 2023-2025.

Paediatric vaccination plays an important role to achieve Sustainable Development Goals (SDGs) set by the United Nations, in particular the target to reduce under-five mortality rate to less than 25 per 1000 live births. Pentavalent vaccine protects children against five deadly diseases: Diphtheria, Tetanus, Pertussis, Hepatitis B and invasive infections caused by Haemophilus Influenza Type b – becoming the foundation of paediatric immunization programs across the world.

Easyfive-TT is the world's first fully liquid wP-based Pentavalent vaccine that was launched in India in 2005. After receiving WHO prequalification in 2008, more than 150 million doses have been supplied to over 75 countries globally. EasyFive-TT is a ready-to-use combination vaccine that does not require preparation by healthcare workers at the clinic, reduces the number of visits to vaccination centres, and reduces the overall cost of immunisation for all stakeholders. As per *Human Vaccines and Immunotherapeutics*<sup>1</sup>, the fully-liquid Pentavalent vaccine has been hailed as a “**breakthrough in India's Universal Immunisation Program**” with having averted more than 7 million cases, averted ~31,000 deaths, and total benefits exceeding US \$ 1 billion in DALY savings in India.

**Dr. Rajesh Jain, Managing Director, Panacea Biotec** said, “We are delighted to receive the notification of UNICEF and PAHO awards for Pentavalent vaccine at this important juncture in Panacea Biotec's journey. **As we celebrate India's 75 years of independence 'Azadi Ka Amrit Mahotsav'**, this showcases the growing role India plays to support global health. We

<sup>1</sup> Bairwa M, Pilania M, Rajput M, Khanna P, Kumar N, Nagar M, Chawla S. Pentavalent vaccine: a major breakthrough in India's Universal Immunization Program. Hum Vaccin Immunother. 2012 Sep;8(9):1314-6. doi: 10.4161/hv.20651. Epub 2012 Aug 16. PMID: 22894968; PMCID: PMC3579914.



are excited to continue to save lives by supporting U.N. Agencies and partners for global immunization programs and to bring to market additional vaccines in coming years to meet programmatic needs of UNICEF and PAHO.”

\*\*\*

#### About Panacea Biotec

Panacea Biotec is a leading pharmaceutical and biotechnology company with established research, manufacturing and marketing capabilities. Panacea Biotec has pioneered in the development of innovative fully-liquid combination vaccines that can be stored at 2-8 degree Celsius temperature. We have also launched world’s first fully liquid wP-IPV based hexavalent vaccine EasySix™ (DTwP-HepB-Hib-IPV) in India in March 2017.

The other key vaccines in portfolio are EasyFour®-TT (DTwP-Hib), IPV based tetravalent vaccine – EasyFour®-Pol (DTwP-IPV) and Bivalent oral polio vaccine (type-1 and type-3). Panacea Biotec’s new vaccines in pipeline are Pneumococcal Conjugate Vaccine - NucoVac-11® and Recombinant Tetravalent Dengue Candidate Vaccine - DengiALL® and Td (tetanus and diphtheria – reduced).

Panacea Biotec remains focused on merging cutting-edge science and technology with an unwavering commitment towards unmet medical needs while ensuring affordability. It has research collaborations with leading national and international research organizations and corporations. Panacea Biotec has around 2,000 employees.

For more information, visit: [www.panaceabiotec.com](http://www.panaceabiotec.com) Follow our news page for the latest updates. Follow us via @PanaceaBiotec and LinkedIn.

\*\*\*



#### For more information:

For Investors	For Media
<p><b>Mr. Devender Gupta</b> Chief Financial Officer and Head Information Technology Tel: + 91-11-41679000 Ext. 1225, 41578011 (Direct) Email: devendergupta@panaceabiotec.com</p>	<p>Mr. P. D. Karan Vice President - Corporate Communication &amp; Business Development Tel: + 91 11 41679000 Extn. 1406, 41578080 (Direct) Mobile: + 91 9312693040, + 91 9810500539 Email: pdkaran@panaceabiotec.com</p>

#### Panacea Biotec Ltd.

CIN: L33117PB1984PLC022350

Registered Office: Ambala-Chandigarh Highway, Lalru - 140 501, Punjab, India. Ph.: +91-1762-505900, Fax: +91-1762-505906.  
e-mail: corporate@panaceabiotec.com website: www.panaceabiotec.com